Clinical Trial

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2021 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is an open-label, multi-center, dose escalation, dose expansion, and cohort expansion phase I/II clinical study of SYHX1903 in patients with relapsed/refractory hematologic malignancies. This trial aims to evaluate the safety, tolerance, pharmacokinetics, and preliminary antitumor activity of SYHX1903 in patients with relapsed/refractory hematologic malignancies.
Trial Details
NCT Number NCT05055791
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma
Enrollment 312 participants
Start Date 2021-12-29
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-09-20 (estimated)
Updated on ClinicalTrials.gov 2021-09-24